Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to 0.51.

  • Myriad Genetics' Equity Ratio fell 2433.45% to 0.51 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.51, marking a year-over-year decrease of 2433.45%. This contributed to the annual value of 0.68 for FY2024, which is 12.49% down from last year.
  • Latest data reveals that Myriad Genetics reported Equity Ratio of 0.51 as of Q3 2025, which was down 2433.45% from 0.57 recorded in Q2 2025.
  • Myriad Genetics' Equity Ratio's 5-year high stood at 0.78 during Q2 2022, with a 5-year trough of 0.51 in Q3 2025.
  • Over the past 5 years, Myriad Genetics' median Equity Ratio value was 0.68 (recorded in 2023), while the average stood at 0.68.
  • As far as peak fluctuations go, Myriad Genetics' Equity Ratio soared by 1801.21% in 2021, and later crashed by 2433.45% in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' Equity Ratio stood at 0.73 in 2021, then grew by 0.84% to 0.74 in 2022, then dropped by 7.56% to 0.68 in 2023, then decreased by 0.12% to 0.68 in 2024, then dropped by 24.95% to 0.51 in 2025.
  • Its Equity Ratio stands at 0.51 for Q3 2025, versus 0.57 for Q2 2025 and 0.7 for Q1 2025.